Emerging applications of nanoparticles for lung cancer diagnosis and therapy

Author:

Sukumar Uday Kumar,Bhushan Bharat,Dubey Poornima,Matai Ishita,Sachdev Abhay,Packirisamy Gopinath

Abstract

Abstract Lung cancer is by far the leading cause of cancer-related mortality worldwide, most of them being active tobacco smokers. Non small cell lung cancer accounts for around 85% to 90% of deaths, whereas the rest is contributed by small cell lung cancer. The extreme lethality of lung cancer arises due to lack of suitable diagnostic procedures for early detection of lung cancer and ineffective conventional therapeutic strategies. In course with desperate attempts to address these issues independently, a multifunctional nanotherapeutic or diagnostic system is being sought as a favorable solution. The manifestation of physiochemical properties of such nanoscale systems is tuned favorably to come up with a versatile cancer cell targeted diagnostic and therapeutic system. Apart from this, the aspect of being at nanoscale by itself confers the system with an advantage of passive accumulation at the site of tumor. This review provides a broad perspective of three major subclasses of such nanoscale therapeutic and diagnostic systems which include polymeric nanoparticles-based approaches, metal nanoparticles-based approaches, and bio-nanoparticles-based approaches. This review work also serves the purpose of gaining an insight into the pros and cons of each of these approaches with a prospective improvement in lung cancer therapeutics and diagnostics.

Publisher

Springer Science and Business Media LLC

Subject

Pharmaceutical Science,Biomedical Engineering,Medicine (miscellaneous),Bioengineering

Reference147 articles.

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D: Global cancer statistics. CA Cancer J. Clin. 2011,61(2):69–90. 10.3322/caac.20107

2. American Lung Association: Trends in Lung Cancer Morbidity and Mortality, Epidemiology and Statistics Unit: Research and Scientific Affairs. . Accessed 28 February 2013 http://www.lung.org/lung-disease/lung-cancer/learning-more-about-lung-cancer/understanding-lung-cancer/ . Accessed 28 February 2013

3. National Cancer Institute: SEER Stat Fact Sheet: Lung and Bronchus. (2002–2008). Accessed 19 December 2012 http://seer.cancer.gov/statfacts/html/lungb.html

4. Edwards DA, Hanes J, Caponetti G, Hrkach J, Ben-Jebria A, Eskew ML, Mintzes J, Lotan N, Langer R: Large porous biodegradable particles for pulmonary drug delivery. Science 1997, 276: 1868–1871. 10.1126/science.276.5320.1868

5. Cochrane Database of Systematic Reviews Non-small Cell Lung Cancer Collaborative Group: Chemotherapy can improve survival rates for non-small cell lung cancer. (2010). Accessed 28 February 2013 http://summaries.cochrane.org/CD002139/chemotherapy-can-improve-survival-rates-for-non-small-cell-lung-cancer (2010). Accessed 28 February 2013

Cited by 93 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3